JonesResearch analyst Soumit Roy downgraded Essa Pharma (EPIX) to Hold from Buy with no price target after the board decided to terminate all trials to conserve cash. The firm, which says “we were wrong in our assessment of masofaniten’s potential,” expects the stock to trade at a 40%-50% discount to cash per share of $2.64 and awaits comments from management on the future steps they plan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EPIX:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
